

Literatura ACTA MEDICINAE 8/2018 Vnitřní lékařství

- 2 **Nová antidiabetika z pohledu kardiologa**
prof. MUDr. Jindřich Špinar, CSc., FESC Interní kardiologická klinika LF MU a FN Brno
prof. MUDr. Lenka Špinarová, Ph.D., FESC I. interní kardiologická klinika, LF MU a FN u sv. Anny v Brně
prof. MUDr. Jiří Vítovec, CSc., FESC Interní kardiologická klinika FNUSA a LF MU, Brno
- 2 **Doporučení České společnosti pro hypertenzi – co nového přinášejí**
prof. MUDr. Miroslav Souček, CSc. II. interní klinika LF MU a ICRC FN u sv. Anny v Brně
- 2 **Praktické přístupy k léčbě dyslipidemií**
prof. MUDr. Helena Vavřková, CSc. III. interní klinika – nefrologická, revmatologická a endokrinologická, LF UP a FN Olomouc
- 2 **Nové možnosti ve farmakoterapii chronického srdečního selhání**
prof. MUDr. Radek Pudil, Ph.D. I. interní kardiologická klinika LF UK a FN Hradec Králové
- 2 **Protidestičková léčba po akutním koronárním syndromu**
MUDr. Ota Hlinomaz, CSc. ICRC, I. interní kardiologická klinika, MU a FN u sv. Anny v Brně
prof. MUDr. Zuzana Mořková, Ph.D. Kardiocentrum, 3. LF UK a FN Královské Vinohrady, Praha
- 3 **Program CANVAS: Canagliflozin – kardiovaskulární a renální vliv u diabetes mellitus 2. typu**
prof. MUDr. Jiří Vítovec, CSc., FESC I. interní kardiologická klinika LF MU a FN u sv. Anny v Brně
prof. MUDr. Jindřich Špinar, CSc., FESC Interní kardiologická klinika LF MU a FN Brno
prof. MUDr. Lenka Špinarová, Ph.D., FESC I. interní kardiologická klinika, LF MU a FN u sv. Anny v Brně
- 3 **Kombinační terapie hypertenze v roce 2018**
MUDr. Ondřej Petrák, Ph.D. Centrum pro výzkum, diagnostiku a léčbu hypertenze, III. interní klinika – klinika endokrinologie a metabolismu, VFN a 1. LF UK, Praha
- 3 **Kombinace rosuvastatinu a ezetimibu v léčbě dyslipidemie**
MUDr. Jiří Veselý Kardiologická ambulance EDUMED, Náchod
- 4 **Betablokátory v léčbě arteriální hypertenze – zaměřeno na metoprolol**
MUDr. Michaela Šnejdrová, Ph.D. Centrum preventivní kardiologie, III. interní klinika 1. LF UK a VFN, Praha
- 4 **Alirokumab v léčbě pacienta s kardiovaskulárním onemocněním a s diabetes mellitus – kazuistika**
doc. MUDr. Peter Jackuliak, PhD. V. interní klinika LFUK a UNB, Bratislava
- 4 **Výsledky studie LixiLan-L – možnost dosažení lepší kompenzace u nemocných s diabetes 2. typu při využití jednoduchého léčebného režimu**
MUDr. Marek Honka Diabetologická a endokrinologická ambulance, Hlučín
- 4 **Aktuální možnosti využití berberinu při léčbě diabetu**
PharmDr. Josef Suchopár Drug Agency, Praha
- 5 **Spánková apnoe – klinické důsledky**
doc. MUDr. Ondřej Ludka, Ph.D. Interní kardiologická klinika FN a LF MU, Mezinárodní centrum klinického výzkumu – Kardiovaskulární spánkové výzkumné centrum, FN u sv. Anny v Brně
- 6 **Subklinická hypothyreóza**
prof. MUDr. Michal Kršek, CSc., MBA II. interní klinika 3. LF UK a FNKV, Praha
- 6 **Současné možnosti a novinky v léčbě IPF**
MUDr. Martina Šterclová, Ph.D. Pneumologická klinika 1. LF UK a Thomayerovy nemocnice, Praha
- 7 **Chronická obstrukční plicní nemoc – nové možnosti léčby**
MUDr. Václava Bártů, Ph.D. Plicní oddělení, Medicon, s. r. o., Praha
- 7 **Postavení inhalačních kortikosteroidů v terapii chronické obstrukční plicní nemoci**
MUDr. Michal Švarc Plicní klinika FN Hradec Králové, Plicní ambulance Edumed, s. r. o., Broumov
- 7 **Selektivní screening Fabryho, Pompeho a Gaucherovy choroby ze suchých krevních kapek u dospělých a dospívajících**
MUDr. Martin Hřebíček, Ph.D. | Ing. Helena Poupětová | Ing. Jitka Honzíková | RNDr. Jana Ledvinová, CSc.
Laboratoř pro studium vzácných nemocí a Diagnostické laboratoře DMP – Enzymologická laboratoř, Klinika dětského a dorostového lékařství UK v Praze, 1. LF a VFN, Praha

Nová antidiabetika z pohledu kardiologa

prof. MUDr. Jindřich Špinar, CSc., FESC Interní kardiologická klinika LF MU a FN Brno

prof. MUDr. Lenka Špinarová, Ph.D., FESC I. interní kardiologická klinika, LF MU a FN u sv. Anny v Brně

prof. MUDr. Jiří Vítovec, CSc., FESC Interní kardiologická klinika FNUSA a LF MU, Brno

- Niessner, A. – Tamargo, J. – Koller, L., et al.: Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. *Eur Heart J*, 2018, 39, s. 2274–2281.
- Seferovic, P. E. – Petrie, M. C. – Filipatos, G. S., et al.: Type 2 diabetes mellitus and heart failure: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. *Eur Heart J*, 2018, 39, doi 10.1002/ehj1170.
- Pipoli, M. F. – Hoes, A. V. – Egevall, S. S., et al.: 2016 European Guidelines on cardiovascular disease prevention. *Eur Heart J*, 2016, 37, s. 2315–2381.
- 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*, 2016, 37, s. 2129–2200.
- Špinar, J. – Hradec, J. – Špinarová, L. – Vítovec, J.: *Souhrn doporučených postupů ESC pro diagnózu a léčbu akutního a chronického srdečního selhání z roku 2016*. Přípraven Českou kardiologickou společností 2016, 58, s. 455–494.
- Vítovec, J. – Špinar, J. – Špinarová, L.: Diabetes mellitus a kardiologická revue a Interní medicína, 2018, 20, s. 118–125.

Doporučení České společnosti pro hypertenzi – co nového přináší

prof. MUDr. Miroslav Souček, CSc. II. interní klinika LF MU a ICRC FN u sv. Anny v Brně

- Filipovský, J. – Widimský, J. jr. – Ceral, J., et al.: Diagnostické a léčebné postupy u arteriální hypertenze – verze 2012. Doporučení České společnosti pro hypertenzi. *Vnitřní lékařství*, 2012, 58, s. 785–801.
- Linhardt, A. – Ceral, J. – Filipovský, J.: Praktický postup České společnosti pro hypertenzi: Měření krevního tlaku 1. část: Obecné principy. *Hypertenze a KV prevence*, 2016, 2, s. 24–27. Viz též www.hypertenze.cz.
- Linhardt, A. – Ceral, J. – Filipovský, J.: Praktický postup České společnosti pro hypertenzi: Měření krevního tlaku 2. část: Měření krevního tlaku v ordinaci. *Hypertenze a KV prevence*, 2016, 2, s. 28–33. Viz též www.hypertenze.cz.
- Filipovský, J. – Seidlerová, J. – Kratochvíl, Z., et al.: Automated compared to manual office blood pressure and to home blood pressure in hypertensive patients. *Blood Press*, 2016, 25, s. 228–234.
- Conen, D. – Aeschbacher, S. – Thijs, L., et al.: Age-specific differences between conventional and ambulatory daytime blood pressure values. *Hypertension*, 2014, 64, s. 1073–1079.
- Mancia, G. – Bombelli, M. – Cuspidi, C., et al.: Cardiovascular risk associated with white-coat hypertension. *Pro Side of the Argument. Hypertension*, 2017, 70, s. 668–675.
- Mancia, G. – Bombelli, M. – Facchetti, R., et al.: Long-term risk of sustained hypertension in white-coat or masked hypertension. *Hypertension*, 2009, 54, s. 226–232.
- Mancia, G. – Bombelli, M. – Facchetti, R., et al.: Increased long-term risk of new-onset diabetes mellitus in white-coat and masked hypertension. *J Hypertension*, 2009, 27, s. 1672–1678.
- Sundstrom, J. – Neovius, M. – Tynelius, P., et al.: Association of blood pressure in late adolescence with subsequent mortality: cohort study of Swedish male conscripts. *BMJ*, 2011, 342, d643, doi:10.1136/bmj.d643.
- Grebła, R. C. – Rodriguez, C. J. – Borrell, L. N., et al.: Prevalence and determinants of isolated systolic hypertension among young adults: the 1999–2004 US National Health And Nutrition Examination Survey. *J Hypertens*, 2010, 28, s. 15–23.
- McEniery, C. M. – Yasmin, S., et al.: ENIGMA Study Investigators: Increased stroke volume and aortic stiffness contribute to isolated systolic hypertension in young adults. *Hypertension*, 2005, 46, s. 221–226.
- The SPRINT Research Group: A randomized trial of intensive versus standard blood-pressure control. *N Engl J Med*, 2015, 373, s. 2103–2116.
- Olde Engberink, R. H. – Frenkel, W. J. – van den Bogaard, B., et al.: Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis. *Hypertension*, 2015, 65, s. 1033–1040.
- Roush, G. C. – Ernst, M. E. – Kostis, J. B., et al.: Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. *Hypertension*, 2015, 65, s. 1041–1046.
- Matsuzaki, M. – Ogihara, T. – Umemoto, S., et al.: Prevention of cardiovascular events with calcium channel blocker – based combination therapies in patients with hypertension: a randomised controlled trial. *J Hypertens*, 2011, 29, s. 1649–1659.
- Yusuf, S. – Teo, K. K. – Pogue, J., et al.: Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med*, 2008, 358, s. 1547–1559.
- McMurray, J. J. – Packer, M. – Desai, A. S., et al.: Angiotensin neprilysin inhibition versus enalapril in heart failure. *N Engl J Med*, 2014, 371, s. 993–1004, doi: 10.1056/NEJMoa1409077.
- Cushman, W. C. – Evans, G. W. – Byington, R. P., et al.: ACCORD Study Group: Effects of intensive blood-pressure control in type 2 diabetes mellitus. *N Engl J Med*, 2010, 362, s. 1575–1585.

Praktické přístupy k léčbě dyslipidemií

prof. MUDr. Helena Vaverková, CSc. III. interní klinika – nefrologická, revmatologická a endokrinologická, LF UP a FN Olomouc

- Catapano, A. L. – Graham, I. – De Backer, G., et al.: 2016 ESC/EAS Guidelines for the Management of Dyslipidemias. *Eur Heart J*, 2011, 32, s. 1769–1818.
- Vrablík, M. – Piňha, J. – Bláha, V., et al.: Stanovisko výboru České společnosti pro aterosklerózu k doporučením ESC/EAS pro diagnostiku a léčbu dyslipidemií z roku 2016. *Vnitřní Léč*, 2018, 64, s. 9–16.
- Cholesterol Treatment Trialists' (CTT) Collaboration; Baigent, C. – Blackwell, L. – Emberson, J., et al.: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet*, 2010, 376, s. 1670–1681.
- Cholesterol Treatment Trialists' (CTT) Collaborators; Mihaylova, B. – Emberson, J. – Blackwell, L., et al.: The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *Lancet*, 2012, 380, s. 581–590.
- Pella, D. – Gvozdičková, A. – Lietava, J., et al.: Myopatie asociovaná se statiny: klinické doporučení Slovenskej asociácie aterosklerózy a České společnosti pro aterosklerózu. *Athero Rev*, 2016, 1, s. 7–13.
- Bultas, J.: Vzájemné srovnání statinů z pohledu farmakologa. *Remedia*, 2013, 23, s. 143–150.
- Cannon, C. P. – Blazing, M. A. – Giugliano, R. P., et al.: IMPROVE-IT Investigators: Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med*, 2015, 372, s. 2387–2397.
- Baigent, C. – Landray, M. J. – Reith, C., et al.: SHARP Investigators: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. *Lancet*, 2011, 377, s. 2181–2192.
- Jun, M. – Foote, C. – Lv, J., et al.: Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. *Lancet*, 2010, 375, s. 1875–1884.
- Wang, D. – Liu, B. – Tao, W., et al.: Fibrates for secondary prevention of cardiovascular disease and stroke. *Cochrane Database Syst Rev*, 2015, 10, CD009580, doi: 10.1002/14651858.CD009580.pub2.
- Jakob, T. – Nordmann, A. J. – Schandelmaier, S., et al.: Fibrates for primary prevention of cardiovascular disease events. *Cochrane Database Syst Rev*, 2016, 11, CD009753, review.
- Sacks, F. M. – Carey, V. J. – Fruchart, J. C.: Combination lipid therapy in type 2 diabetes. *N Engl J Med*, 2010, 363, s. 692–694; autorova odpověď s. 694–695.
- Rajamani, K. – Colman, P. G. – Li, L. P., et al.: FIELD study investigators: Effect of fenofibrate on amputation events people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of randomised controlled trial. *Lancet*, 2009, 373, s. 1780–1788.
- Sabatine, M. S. – Giugliano, R. P. – Keech, A. C., et al.: FOURIER Steering Committee and investigators: Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med*, 2017, 376, s. 1713–1722.
- ODYSSEY Outcomes study. American College of Cardiology (ACC) 2018 Annual Scientific Session: prezentace 401–408. Prezentováno 10. 3. 2018.

Nové možnosti ve farmakoterapii chronického srdečního selhání

prof. MUDr. Radek Pudil, Ph.D. I. interní kardiologická klinika LF UK a FN Hradec Králové

- Dalzell, J. R. – Seed, A. – Berry, C., et al.: Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat. *Cardiovasc Ther*, 2014, 32, s. 13–18.
- Kaplinsky, E.: Sacubitril/valsartan in heart failure: latest evidence and place in therapy. *Adv Chronic Dis*, 2016, 7, s. 278–290.
- McMurray, J. J. V. – Packer, M. – Desai, A. S., et al.: Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). *Eur J Heart Failure*, 2013, 15, s. 1062–1073.
- McMurray, J. J. V. – Packer, M. – Desai, A. S., et al.: PARADIGM-HF Investigators and Committees: Angiotensin-neprilysin inhibition versus enalapril in heart failure. *N Engl J Med*, 2014, 371, s. 993–1004.
- Ponikowski, P. – Voors, A. A. – Anker, S. D., et al.: 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). *Eur Heart J*, 2016, 37, s. 2129–2200.
- Špinar, J., et al.: Summary of the 2016 ESC Guidelines on the diagnosis and treatment of acute and chronic heart failure. Prepared by the Czech Society of Cardiology. *Cor et Vasa*, 2016, 58, s. e530–e568.

Protidestičková léčba po akutním koronárním syndromu

MUDr. Ota Hlinomaz, CSc. ICRC, I. interní kardiologická klinika, MU a FN u sv. Anny v Brně
prof. MUDr. Zuzana Motovská, Ph.D. Kardiocentrum, 3. LF UK a FN Královské Vinohrady, Praha

- 1 Roffi, M. – Patrono, C. – Collet, J. P., et al.: 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting with out persistent ST-segment elevation. *Eur Heart J*, 2016, 37, s. 267–315.
- 2 Ibanez, B. – James, S. – Agewall, S., et al.: 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. *Eur Heart J*, 2017, 00, s. 1–66.
- 3 Valgimigli, M. – Bueno, H. – Byrne, A. R., et al.: 2017 ESC focus update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. *Eur Heart J*, 2017, 0, s. 1–48.
- 4 Motovska, Z. – Hlinomaz, O. – Miklik, R., et al.; PRAGUE-18 Study Group: Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: multicenter randomized PRAGUE-18 study. *Circulation*, 2016, 134, s. 1603–1612, Epub 30. 8. 2016.
- 5 Motovska, Z. – Hlinomaz, O. – Kala, P.; PRAGUE-18 Investigators: Response by Motovska et al to Letter Regarding Article: „Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: multicenter randomized PRAGUE-18 Study“. *Circulation*, 2017, 135, s. e887–e888, doi: 10.1161/CIRCULATIONAHA.117.027476.
- 6 Motovska, Z. – Hlinomaz, O. – Kala, P., et al.; PRAGUE-18 Study Group: 1-Year outcomes of patients undergoing primary angioplasty for myocardial infarction treated with prasugrel versus ticagrelor. *J Am Coll Cardiol*, 2018, 71, s. 371–381, doi: 10.1016/j.jacc.2017.11.008, Epub 14. 11. 2017.
- 7 Motovska, Z. – Hlinomaz, O. – Kala, P.: Reply: Cost of therapies in acute coronary syndromes: a relevant factor not reflected in the trials. *J Am Coll Cardiol*, 2018, 71, s. 2711–2712.

Program CANVAS: Canagliflozin – kardiovaskulární a renální vliv u diabetes mellitus 2. typu

prof. MUDr. Jiří Vítovec, CSc., FESC I. interní kardiologická klinika LF MU a FN u sv. Anny v Brně
prof. MUDr. Jindřich Špinar, CSc., FESC Interní kardiologická klinika LF MU a FN Brno
prof. MUDr. Lenka Špinarová, Ph.D., FESC I. interní kardiologická klinika, LF MU a FN u sv. Anny v Brně

- 1 Niessner, A. – Tamargo, J. – Koller, L., et al.: Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the ESC Working Group on Cardiovascular Pharmacotherapy. *Europ Heart J*, 2018, 39, s. 2274–2281.
- 2 Neal, B. – Perkovic, V. – Mahaffey, K. W., et al.; CANVAS Program Collaborative Group: Canagliflozin and cardiovascular and renal events in type 2 diabetes. *N Engl J Med*, 2017, 377, s. 644–657.
- 3 Rådholm, K. – Figtree, G. – Perkovic, V., et al.: Canagliflozin and heart failure in type 2 diabetes mellitus. Results from the CANVAS program. *Circulation*, 2018, 138, s. 458–468.
- 4 Edelsberger, T.: Glukoretika (inhibitory SGLT2, glifloziny) v léčbě diabetu. *Remedia*, 2011, 21, s. 46–53.
- 5 Heerspink, H. J. – Perkins B. A. – Fitchett, D. H., et al.: Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. *Circulation*, 2016, 134, s. 752–772.
- 6 Wilding, J. P. H. – Woo, V. – Soler, N. G., et al.: Sustained effectiveness of dapagliflozin over 48 weeks in patients with Type 2 diabetes poorly controlled with insulin. *Diabetes*, 2010, 59, suppl. 1, abstrakt 0021–LB.
- 7 Adamiková, A.: Canagliflozin – místo v léčbě diabetes mellitus 2. typu. *Farmakoterapeutická Revue*, 2018, 1, s. 8–13.
- 8 SPC Invokana. Dostupné z: <http://www.sukl.cz/modules/medication/detail.php?code=0194605&tab=texts>, vyhledáno 23. 8. 2018.
- 9 Bode, B. – Stenlof, K. – Harris, S.: Long-term efficacy and safety of CANA over 104 weeks in patients aged 55 to 80 years with type 2 diabetes. *Diabetes Obes Metab*, 2015, 17, s. 294–303.
- 10 Yuan, Z. – DeFalco, F. J. – Ryan, P. B., et al.: Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study. *Diabetes Obes Metab*, 2018, 20, s. 582–589.
- 11 Ryan, P. B. – Buse, J. B. – Schuemie, M. J., et al.: Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D). *Diabetes Obes Metab*, 2018, s. 1–13.
- 12 Jardine, M. J. – Mahaffey, K. W. – Neal, B., et al.: The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CRENDENCE) study rationale, design and baseline characteristics. *Am J Nephrol*, 2017, 46, s. 462–472.

Kombinační terapie hypertenze v roce 2018

MUDr. Ondřej Petrák, Ph.D. Centrum pro výzkum, diagnostiku a léčbu hypertenze, III. interní klinika – klinika endokrinologie a metabolismu, VFN a 1. LF UK, Praha

- 1 Cifková, R. – Škodová, Z. – Bruthans, J. – Holub, J. – Adámková, V. – Jozifová, M. – Galovcová, M. – Wohlfahrt, P. – Krajcoviechová, A. – Petržílková, Z. – Lánská, V.: Longitudinal trends in cardiovascular mortality and blood pressure levels, prevalence, awareness, treatment, and control of hypertension in the Czech population from 1985 to 2007/2008. *J Hypertens*, 2010, 28, s. 2196–2203.
- 2 He, F. J. – MacGregor, G. A.: A comprehensive review on salt and health and current experience of worldwide salt reduction programmes. *J Human Hypertens*, 2009, 23, s. 363–384.
- 3 Erdine, S. V. – Aran, S. N.: Current status of hypertension control around the world. *Clin Exp Hypertens*, 2004, 26, s. 731–738.
- 4 Widimský, Jr. J. – Filipovský, J. – Ceral, J. – Cifková, R. – Linhart, A. – Monhart, V. – Rosolová, H. – Seidlerová Mlíková, J. – Souček, M. – Špinar, J. – Tesař, V. – Vítovec, J. – Zelinka, T.: Doporučení pro diagnostiku a léčbu arteriální hypertenze ČHS 2017. *Hypertenze & kardiovaskulární prevence*, 2018, 7, s. 1–20.
- 5 Wald, D. S. – Law, M. – Morris, J. K., et al.: Combination therapy versus monotherapy in reducing blood pressure: Meta-analysis on 11,000 participants from 42 trials. *Am J Med*, 2009, 122, s. 290–300.
- 6 Corrao, G. – Nicotra, F. – Parodi, A., et al.: Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. *Hypertension*, 2011, 58, s. 566–572.
- 7 Gupta, A. K. – Arshad, S. – Poulter, N. R.: Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: A meta-analysis. *Hypertension*, 2010, 55, s. 399–407.
- 8 Neldam, S. – Edwards, C. – Lang, M. – Jones, R.; Teamsta Investigators: Long-term tolerability and efficacy of single-pill combinations of telmisartan 40-80 mg plus amlodipine 5 or 10 mg in patients whose blood pressure was not initially controlled by amlodipine 5-10 mg: Open-label, long-term follow-ups of the Teamsta-5 and Teamsta-10 studies. *Curr Ther Res Clin Exp*, 2012, 73, s. 65–84.
- 9 Germino, F. W.: Which diuretic is the preferred agent for treating essential hypertension: Hydrochlorothiazide or chlorthalidone? *Current Cardiology Reports*, 2012, 14, s. 673–677.
- 10 Roush, G. C. – Ernst, M. E. – Kostis, J. B., et al.: Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: Antihypertensive and metabolic effects. *Hypertension*, 2015, 65, s. 1041–1046.
- 11 Littlejohn, T. W. 3rd – Majul, C. R. – Olvera, R., et al.: Results of treatment with telmisartan amlodipine in hypertensive patients. *J Clin Hypertens (Greenwich)*, 2009, 11, s. 207–213.

Kombinace rosuvastatinu a ezetimibu v léčbě dyslipidemie

MUDr. Jiří Veselý Kardiologická ambulance EDUMED, Náchod

- 1 Jones, P. H. – Davidson, M. H. – Stein, E. A., et al.; for the STELLAR Study Group: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). *Am J Cardiol*, 2003, 92, s. 152–160.
- 2 Crouse, J. R. – Raichlen, J. S. – Riley, W. A., et al.: Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis. The METEOR Trial. *JAMA*, 2007, 297, s. 1344–1353.
- 3 Nissen, S. E. – Nicholls, S. J. – Sipahi, I., et al.: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial. *JAMA*, 2006, 295, s. 1556–1565.
- 4 Kjekus, J. – Apetrei, E. – Barrios, V., et al.; CORONA Study Group: Rosuvastatin in older patients with systolic heart failure. *N Engl J Med*, 2007, 357, s. 2248–2261.
- 5 Fellström, B. C. – Jardine, A. G. – Schmieder, R. E., et al.; AURORA Study Group: Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. *N Engl J Med*, 2009, 360, s. 1395–1407.
- 6 Ridker, P. M. – Danielson, E. – Fonseca, F. A., et al.; on behalf of the JUPITER Study Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med*, 2008, 359, s. 2195–2207.
- 7 Ridker, P. M. – Pradhan, A. – MacFadyen, J. G., et al.: Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. *Lancet*, 2012, 380, s. 565–571.
- 8 Ridker, P. M. – Mora, S., et al.: Justification for the use of statins in primary prevention: an intervention trial evaluating rosuvastatin (JUPITER)-can C-reactive protein be used to target statin therapy in primary prevention? *Am J Cardiol*, 2006, 97, s. 33A–41A.
- 9 Vaverková, H.: Rosuvastatin. *Remedia*, 2008, s. 324–330.
- 10 Vrablík, M.: Rosuvastatin. *Kap Kardiol*, 2011, 3, s. 22–25.
- 11 Bultas, J.: Vzájemně srovnání statinů z pohledu farmakologa. *Remedia*, 2013, 23, s. 143–150.
- 12 Bultas, J.: Ezetimib – selektivní inhibitor absorpce cholesterolu. *Remedia*, 2004, s. 214–216.
- 13 Sharp Collaborative Group: Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. *Am Heart J*, 2010, 160, s. 785–794.e10.
- 14 Baigent, C. – Landray, M. J. – Reith, C., et al.: The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. *Lancet*, 2011, 377, s. 2181–2192.
- 15 Špinar, J. – Špinarová, L. – Vítovec, J.: IMPROVED Reduction of Outcomes: Vitorin Efficacy International Trial (studie IMPROVE-IT). *Vnitř Lek*, 2014, 60, s. 1095–1101.
- 16 Blazing, M. A. – Giugliano, R. P. – Cannon, C. P., et al.: Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline

- characteristics of the IMPROVE-IT study population. *Am Heart J*, 2014, 168, s. 205–212.
- 17 Cannon, C. H. P. – Blazing, M. A. – Giugliano, R. P., et al.: for the IMPROVE-IT Investigators: Ezetimibe added to statin therapy after acute coronary syndromes. *NEJM*, 2015, 372, s. 2387–2397.
- 18 Janský, P. – Rosolová, H. – Vrablík, M.: Souhrn Doporučených postupů ESC/EAS pro diagnostiku a léčbu dyslipidemií z roku 2016 (2016 ESC/EAS Guidelines for the management of dyslipidaemias: Summary of the document prepared by the Czech Society of Cardiology). *Cor et Vasa*, 2017, 59, s. e389–e415.
- 19 Vrablík, M.: *Farmakoterapie dyslipidemie*. Maxdorf, Praha, 2016.
- 20 Bays, H. E., et al.: Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). *Am J Cardiol*, 2011, 108, s. 523–530.
- 21 Kim, K. – Kim, S. – Yoon, Y. W., et al.: Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROSuvastatin and eZetimibe). *Cardiovascular Therapeutics*, 2016, 34, s. 371–382.
- 22 Kim, H. – Choi, H. Y. – Kim, Y. H., et al.: Pharmacokinetic interactions and tolerability of rosuvastatin and ezetimibe: an open-label, randomized, multiple-dose, crossover study in healthy male volunteers. *Drug Design, Development and Therapy*, 2018, 12, s. 815–821.

Betablokátory v léčbě arteriální hypertenze – zaměřeno na metoprolol

MUDr. Michaela Šnejdrová, Ph.D. Centrum preventivní kardiologie, III. interní klinika 1. LF UK a VFN, Praha

- 1 Dahlof, B. – Sever, P. S. – Poulter, N. R., et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. *Lancet*, 2005, 366, s. 895–906.
- 2 Dahlof, B. – Devereux, R. B. – Kjeldsen, S. E., et al.: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. *Lancet*, 2002, 359, s. 995–1003.
- 3 Thomopoulos, C. – Parati, G. – Zanchetti, A.: Effects of blood pressure lowering on outcome incidence in hypertension: Effects of various classes of antihypertensive drugs—overview and meta-analyses. *J Hypertens*, 2015, 33, s. 195–211.
- 4 Williams, B. – Mancia, G. – Spiering, W., et al.: 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J*, 2018, 00, s. 1–98.
- 5 Dostupné z: <http://www.sukl.cz/download/spc/SPC19992.pdf>, vyhledáno 31. 8. 2018.
- 6 Vitovec, J. – Špinar, J.: Metoprolol. *Remedia*, 2000, 10, s. 76–86.
- 7 Petrák, O.: Negativní metabolické působení antihypertenziv. Je to vůbec klinicky relevantní? *Athero Rev*, 2016, 1, s. 74–79.
- 8 Bangalore, S. – Parkar, S. – Grossman, E., et al.: A meta-analysis of 94,492 patients with hypertension treated with betablockers to determine the risk of the new-onset diabetes mellitus. *Am J Cardiol*, 2007, 100, s. 1254–1262.

Alirokumab v léčbě pacienta s kardiovaskulárním onemocněním a s diabetes mellitus – kazuistika

doc. MUDr. Peter Jackuliak, PhD. V. interná klinika LFUK a UNB, Bratislava

- 1 Mihaylova, B. – Emberson, J. – Blackwell, L., et al.: The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *Lancet*, 2012, 380, s. 581–590.
- 2 Catapano, A. L. – Graham, I. – De Backer, G., et al.: 2016 ESC/EAS Guidelines for the management of dyslipidaemias. *Eur Heart J*, 2016, 37, s. 2999–3058.
- 3 Piepoli, M. F. – Hoes, A. W. – Agewall, S., et al.: 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Eur Heart J*, 2016, 37, s. 2315–2381.
- 4 Pencina, M. J. – Navar-Boggan, A. M. – D'Agostino, R. B. S., et al.: Application of new cholesterol guidelines to a population-based sample. *New Eng J Med*, 2014, 370, s. 1422–1431.
- 5 Kotseva, K. – Wood, D. – De Bacquer, D., et al.: EUROASPIRE IV: A European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. *Eur J Prev Cardiol*, 2016, 23, s. 636–648.
- 6 Colantonio, L. D. – Huang, L. – Monda, K. L., et al.: Adherence to high-intensity statins following a myocardial infarction hospitalization among medicare beneficiaries. *JAMA Cardiology*, 2017, 2, s. 890–895.
- 7 Landmesser, U. – Chapman, M. J. – Stock, J. K., et al.: 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. *Europ Heart J*, 2017, ehx549-ehx.
- 8 Urban, D. – Pöbs, J. – Böhm, M., et al.: Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. *J Am Col Cardiol*, 2013, 62, s. 1401–1408.
- 9 Kosmas, C. E. – DeJesus, E. – Morcelo, R., et al.: Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy. *Drugs in Context*, 2017, 6, 212511.
- 10 Kosenko, T. – Golder, M. – Leblond, G., et al.: Low density lipoprotein binds to proprotein convertase subtilisin/kexin type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated low density lipoprotein receptor degradation. *J Biol Chemistry*, 2013, 288, s. 8279–8288.
- 11 Greig, S. L. – Deeks, E. D.: Alirocumab: a review in hypercholesterolemia. *Am J Card Drugs*, 2016, 16, s. 141–152.
- 12 McKenney, J. M. – Koren, M. J. – Kereiakes, D. J., et al.: Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. *J Am Col Cardiol*, 2012, 59, s. 2344–2353.
- 13 Cannon, C. P. – Cariou, B. – Blom, D., et al.: Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. *Eur Heart J*, 2015, 36, s. 1186–1194.
- 14 El Shahawy, M. – Cannon, C. P. – Blom, D. J., et al.: Efficacy and safety of alirocumab versus ezetimibe over 2 years (from ODYSSEY COMBO II). *Am J Cardiol*, 2017, 120, s. 931–939.

Výsledky studie LixiLan-L – možnost dosažení lepší kompenzace u nemocných s diabetem 2. typu při využití jednoduchého léčebného režimu

MUDr. Marek Honka Diabetologická a endokrinologická ambulance, Hlučín

- 1 Rosenstock, J. – Schwartz, S. L. – Clark, C. M. Jr., et al.: Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. *Diabetes Care*, 2001, 24, s. 631–636.
- 2 Charbonnel, B. – Bertolini, M. – Tinahones, F. J., et al.: Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis. *J Diabetes Complications*, 2014, 28, s. 880–886.
- 3 Gutniak, M. – Orskov, C. – Holst, J. J., et al.: Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. *N Engl J Med*, 1992, 326, s. 1316–1322.
- 4 Raccach, D. – Lin, J. – Wang, E., et al.: Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials. *J Diabetes Complications*, 2014, 28, s. 40–44.
- 5 Riddle, M. C. – Aronson, R. – Home, P., et al.: Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). *Diabetes Care*, 2013, 36, s. 2489–2496.
- 6 Inzucchi, S. E. – Bergenstal, R. M. – Buse, J. B., et al.: Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*, 2015, 38, s. 140–149.
- 7 Aroda, V. R. – Rosenstock, J. – Wysham, C., et al.: Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: the LixiLan-L randomized trial. *Diabetes Care*, 2016, 39, s. 1972–1980.
- 8 Garber, A. J.: Treat-to-target trials: uses, interpretation and review of concepts. *Diabetes Obes Metab*, 2014, 16, s. 193–205.
- 9 Rosenstock, J. – Diamant, M. – Aroda, V. R., et al.: LixiLan PoC Study Group: Efficacy and safety of LixiLan, a titratable fixed-ratio combination of lixisenatide and insulin glargine, versus insulin glargine in type 2 diabetes inadequately controlled on metformin monotherapy: the LixiLan proof-of-concept randomized trial. *Diabetes Care*, 2016, 39, s. 1579–1586.
- 10 Aroda, V. – Rosenstock, J. – Wysham, C., et al.: Efficacy and safety of the insulin glargine/lixisenatide fixed-ratio combination vs. insulin glargine in patients with T2DM: the LixiLan-L Trial (Abstract). *Diabetes Care*, 2016, 65 (suppl. 1), s. A62.
- 11 Rosenstock, J. – Guerci, B. – Hanefeld, M., et al.: GetGoal Duo-2 Trial Investigators: Prandial options to advance basal insulin glargine therapy: testing lixisenatide plus basal insulin versus insulin glulisine either as basal-plus or basal-bolus in type 2 diabetes: the GetGoal Duo-2 trial. *Diabetes Care*, 2016, 39, s. 1318–1328.
- 12 Lingvay, I. – Manghi, F. P. – García-Hernández, P., et al.: DUAL V Investigators: Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trial. *JAMA*, 2016, 315, s. 898–907.
- 13 Frias, J., et al.: ADA 2017, San Diego (CA), USA: Poster 1084-P. Dostupné z: <https://ada.scientificposters.com/epsSearchADA.cfm>, vyhledáno 21. 8. 2018.

Aktuální možnosti využití berberinu při léčbě diabetu

PharmDr. Josef Suchopár Drug Agency, Praha

- 1 Ko, B. S. – Choi, S. B. – Park, S. K., et al.: Insulin sensitizing and insulinotropic action of berberine from *Cortidis Rhizoma*. *Biol Pharm Bulletin*, 2005, 28, s. 1431–1437.
- 2 Lee, Y. S. – Kim, W. S. – Kim, K. H., et al.: Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. *Diabetes*, 2006, 55,

s. 2256–2264.

- 3 Lu, S. S. – Yu, Y.-L. – Zhu, J.-H., et al.: Berberine promotes glucagon-like peptide-1 (7–36) amide secretion in streptozotocin-induced diabetic rats. *J Endocrinol*, 2009, 200, s. 159–165.
- 4 Xia, X. – Yan, J. – Shen, Y., et al.: Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis. *PLoS ONE*, 2011, 6, e16556.
- 5 Yin, J. – Gao, Z. – Liu, D., et al.: Berberine improves glucose metabolism through induction of glycolysis. *Am J Physiol Endocrinol Metab*, 2008, 294, s. E148–E156.
- 6 Zhou, J. J. – Zhou, S. W. – Zhang, K. B., et al.: Chronic effects of berberine on blood, liver glucolipid metabolism and liver PPARs expression in diabetic hyperlipidemic rats. *Biol Pharm Bulletin*, 2008, 31, s. 1169–1176.
- 7 Zhang, Q. – Xiao, X. H. – Wang, T., et al.: Mechanism of berberine regulating glucose and lipid metabolism studied with RT-PCR array. *Zhong Guo Shi Yan Dong Wu Xue Bao*, 2011, 9, s. 29–33.
- 8 Liu, C. S. – Zheng, Y. R. – Zhang, Y. F., et al.: Research progress on berberine with a special focus on its oral bioavailability. *Fitoterapia*, 2016, 109, s. 274–282.
- 9 Guo, Y. – Li, F. – Ma, X., et al.: CYP2D plays a major role in berberine metabolism in liver of mice and humans. *Xenobiotica*, 2011, 41,

s. 996–1005.

- 10 Yin, J. – Xing, H. – Ye, J.: Efficacy of berberine in patients with type 2 diabetes mellitus. *Metabolism*, 2008, 57, s. 712–717.
- 11 Zhang, Y. – Li, X. – Zou, D., et al.: Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. *J Clin Endocrinol Metab*, 2008, 93, s. 2559–2565.
- 12 Lan, J. – Zhao, Y. – Dong, F., et al.: Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. *J Ethnopharmacol*, 2015, 161, s. 69–81.

Spánková apnoe – klinické důsledky

doc. MUDr. Ondřej Ludka, Ph.D. Interní kardiologická klinika FN a LF MU, Mezinárodní centrum klinického výzkumu – Kardiologické spánkové výzkumné centrum, FN u sv. Anny v Brně

- 1 Tkáčová, R.: *Spánková apnoe a ochorenia kardiokulárneho systému*. Praha, Galén, 2006.
- 2 Tkáčová, R. – Hall, M. J. – Liu, P. P., et al.: Left ventricular volume in patients with heart failure and Cheyne-Stokes respiration during sleep. *Am J Respir Crit Care Med*, 1997, 156, s. 1549–1555.
- 3 Solin, P. – Bergin, P. – Richardson, M., et al.: Influence of pulmonary capillary wedge pressure on central apnea in heart failure. *Circulation*, 1999, 99, s. 1574–1579.
- 4 Lorenzi-Filho, G. – Azevedo, E. R. – Parker, J. D., et al.: Relationship of carbon dioxide tension in arterial blood to pulmonary wedge pressure in heart failure. *Eur Respir J*, 2002, 19, s. 37–40.
- 5 Peppard, P. E. – Young, T. – Palta, M., et al.: Longitudinal study of moderate weight change and sleep-disordered breathing. *JAMA*, 2000, 284, s. 3015–3021.
- 6 He, J. – Kryger, M. H. – Zoric, F. J., et al.: Mortality and apnea index in obstructive in obstructive sleep apnea-hypopnea: hypertension and other ill effects. *Am J Hypertens*, 2009, 22, s. 474–483.
- 7 Shah, N. A. – Yaggi, H. K. – Concato, J., et al.: Obstructive sleep apnea as a risk factor for coronary events or cardiovascular death. *Sleep Breath*, 2010, 14, s. 131–136.
- 8 Young, T. – Finn, L. – Peppard, P. E., et al.: Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. *Sleep*, 2008, 31, s. 1071–1078.
- 9 Punjabi, N. M. – Caffo, B. S. – Goodwin, J. L., et al.: Sleep-disordered breathing and mortality: a prospective cohort study. *PLoS Med*, 2009, 6, e1000132.
- 10 Jelic, S. – Le Jemtel, T. H.: Inflammation, oxidative stress, and the vascular endothelium in obstructive sleep apnea. *Trends Cardiovasc Med*, 2008, 18, s. 253–260.
- 11 Sanner, B. M. – Konermann, M. – Tepel, M., et al.: Platelet function in patients with obstructive sleep apnoea syndrome. *Eur Respir J*, 2000, 16, s. 648–652.
- 12 Marin, J. M. – Carrizo, S. J. – Vicente, E., et al.: Long-term cardiovascular outcomes in men with or without treatment with continuous positive airway pressure: an observational study. *Lancet*, 2005, 365, s. 1046–1053.
- 13 Doherty, L. S. – Kiely, J. L. – Swan, V., et al.: Long-term effects of nasal continuous positive airway pressure therapy on cardiovascular outcomes in sleep apnea syndrome. *Chest*, 2005, 127, s. 2076–2084.
- 14 Somers, V. K. – White, D. P. – Amin, R., et al.: Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. *J Am Coll Cardiol*, 2008, 52, s. 686–717.
- 15 Hermida, R. C. – Zamarron, C. – Ayala, D. E., et al.: Effect of continuous positive airway pressure on ambulatory blood pressure in patients with obstructive sleep apnoea. *Blood Press Monit*, 2004, 9, s. 193–202.
- 16 Dart, R. A. – Gregore, J. R. – Guterman, D. D., et al.: The association of hypertension and secondary cardiovascular disease with sleep-disordered breathing. *Chest*, 2003, 123, s. 244–260.
- 17 Logan, A. G. – Perlikowski, S. M. – Tkacova, R., et al.: High prevalence of unrecognized sleep apnea in drug-resistant hypertension. *J Hypertens*, 2001, 19, s. 2271–2277.
- 18 Nieto, F. J. – Young, T. B. – Lind, B. K., et al.: Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. *JAMA*, 2000, 283, s. 1829–1836.
- 19 Haas, D. C. – Foster, G. L. – Nieto, F. J., et al.: Age-dependent association between sleep-disordered breathing and hypertension: importance of discriminating between systolic/diastolic hypertension and isolated systolic hypertension in the Sleep Heart Health Study. *Circulation*, 2005, 111, s. 614–621.
- 20 Suzuki, M. – Guilleminault, C. – Otsuka, K., et al.: Blood pressure “dipping” and “non-dipping” in obstructive sleep apnea syndrome patients. *Sleep*, 1996, 19, s. 382–387.
- 21 Ancoli-Israel, S. – Stepnowsky, C. – Dimsdale, J., et al.: The effect of race and sleep-disordered breathing on nocturnal BP “dipping”: analyses in an older population. *Chest*, 2002, 122, s. 1148–1155.
- 22 Somers, V. K. – Dyken, M. E. – Clary, M. P., et al.: Sympathetic neural mechanisms in obstructive sleep apnea. *J Clin Invest*, 1995, 96, s. 1897–1904.
- 23 Bazzano, L. A. – Khan, Z. – Reynolds, K., et al.: Effect of nocturnal nasal continuous positive airway pressure on blood pressure in obstructive sleep apnea. *Hypertension*, 2007, 50, s. 417–423.
- 24 Haentjens, P. – Van Meerhaeghe, A. – Moscariello, A., et al.: The impact of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea syndrome: evidence from a meta-analysis of placebo-controlled randomized trials. *Arch Intern Med*, 2007, 167, s. 757–764.
- 25 Alajmi, M. – Mulgrew, A. T. – Fox, J., et al.: Impact of continuous positive airway pressure therapy on blood pressure in patients with obstructive sleep apnea hypopnea: a meta-analysis of randomized controlled trials. *Lung*, 2007, 185, s. 67–72.
- 26 Malik, J. – Drake, C. L. – Hudgel, D. W.: Variables affecting the change in systemic blood pressure in response to nasal CPAP in obstructive sleep apnea patients. *Sleep Breath*, 2008, 12, s. 47–52.
- 27 Mehra, R. – Principe-Rodriguez, K. – Kirchner, H. L., et al.: Sleep apnea in acute coronary syndrome: high prevalence but low impact on 6-month outcomes. *Sleep Med*, 2006, 7, s. 521–528.
- 28 Lee, C. H. – Khoo, S. M. – Tai, B. C., et al.: Obstructive sleep apnea in patients admitted for acute myocardial infarction. Prevalence, predictors, and effect on microvascular perfusion. *Chest*, 2009, 135, s. 1488–1495.
- 29 Ludka, O. – Stepanova, R. – Vyskocilova, M., et al.: Sleep apnea prevalence in acute myocardial infarction – the Sleep Apnea in Post-acute Myocardial Infarction Patients (SAPAMI) Study. *Int J Cardiol*, 2014, 176, s. 13–19.
- 30 Konecny, T. – Kuniyoshi, F. H. – Orban, M., et al.: Under-diagnosis of sleep apnea in patients after acute myocardial infarction. *J Am Coll Cardiol*, 2010, 56, s. 742–743.
- 31 Quyyumi, A. A. – Efthimiou, J. – Quyyumi, A., et al.: Nocturnal angina: precipitating factors in patients with coronary artery disease and those with variant angina. *Br Heart J*, 1986, 56, s. 346–352.
- 32 Hanly, P. A. – Samson, Z. – Zuberi, N., et al.: ST-segment depression during sleep in obstructive sleep apnea. *Am J Cardiol*, 1993, 71, s. 1341–1345.
- 33 Orea-Tejada, A. – Valencia-Flores, M. – Castillo-Martinez, L., et al.: Abnormal SPECT myocardial perfusion imaging during periods of obstructive sleep apnea in korbic obese patients without known heart disease. *Rev Incest Clin*, 2003, 55, s. 18–25.
- 34 Turmel, J. – Sériés, F. – Boulet, L. P., et al.: Relationship between atherosclerosis and the sleep apnea syndrome: an intravascular ultrasound study. *Int J Cardiol*, 2009, 132, s. 203–209.
- 35 Sorajja, D. – Gami, A. S. – Somers, V. K., et al.: Independent association between obstructive sleep apnea and subclinical coronary artery disease. *Chest*, 2008, 133, s. 927–933.
- 36 Yumino, D. – Tsurumi, Y. – Takagi, A., et al.: Impact of obstructive sleep apnea on clinical and angiographic outcomes following percutaneous coronary intervention in patients with acute coronary syndrome. *Am J Cardiol*, 2007, 99, s. 26–30.
- 37 Lee, C. H. – Khoo, S. M. – Chan, M. Y., et al.: Severe obstructive sleep apnea and outcomes following myocardial infarction. *J Clin Sleep Med*, 2011, 7, s. 616–621.
- 38 Nakashima, H. – Katayama, T. – Takagi, C., et al.: Obstructive sleep apnoea inhibits the recovery of left ventricular function in patients with acute myocardial infarction. *Eur Heart J*, 2006, 27, s. 2317–2322.
- 39 Jelic, S. – Le Jemtel, T. H., et al.: Inflammation, oxidative stress, and the vascular endothelium in obstructive sleep apnea. *Trends Cardiovasc Med*, 2008, 18, s. 253–260.
- 40 Philip, P. – Guilleminault, C.: ST segment abnormality, angina during sleep and obstructive sleep apnea. *Sleep*, 1993, 16, s. 558–559.
- 41 Milleron, O. – Pilière, R. – Foucher, A., et al.: Benefits of obstructive sleep apnoea treatment in coronary artery disease: a long-term follow-up study. *Eur Heart J*, 2004, 25, s. 728–734.
- 42 Garcia-Rio, F. – Alonso-Fernández, A. – Armada, E., et al.: CPAP effect on recurrent episodes in patients with sleep apnea and myocardial infarction. *Int J Cardiol*, 2013, 168, s. 1328–1335.
- 43 Cassar, A. – Morgenthaler, T. L. – Lennon, R. J., et al.: Treatment of obstructive sleep apnea is associated with decreased cardiac death after percutaneous coronary intervention. *J Am Coll Cardiol*, 2007, 50, s. 1310–1314.
- 44 McEvoy, R. D. – Antic, N. A. – Heeley, E., et al.: CPAP for prevention of cardiovascular events in obstructive sleep apnea. *N Engl J Med*, 2016, 375, s. 919–931.
- 45 Guilleminault, C. – Connolly, S. J. – Winkle, R. A.: Cardiac arrhythmia and conduction disturbances during sleep in 400 patients with sleep apnea syndrome. *Am J Cardiol*, 1983, 52, s. 490–494.
- 46 Tilkian, A. G. – Guilleminault, C. – Schroeder, J. S., et al.: Sleep-induced apnea syndrome. Prevalence of cardiac arrhythmias and their reversal after tracheostomy. *Am J Med*, 1977, 63, s. 348–358.
- 47 Becker, H. – Brandenburg, U. – Peter, J. H., et al.: Reversal of sinus arrest and atrioventricular conduction block in patients with sleep apnea during nasal continuous positive airway pressure. *Am J Respir Crit Care Med*, 1995, 151, s. 215–218.
- 48 Flemons, W. W. – Remmers, J. E. – Gillis, A. M.: Sleep apnea and cardiac arrhythmias: is there a relationship? *Am Rev Respir Dis*, 1993, 148, s. 618–621.
- 49 Mehra, R. – Benjamin, E. J. – Shahar, E., et al.: Association of nocturnal arrhythmias with sleep-disordered breathing: The Sleep Heart Health Study. *Am J Respir Crit Care Med*, 2006, 173, s. 910–916.
- 50 Garrigue, S. – Pepin, J. L. – Defaye, P., et al.: High prevalence of sleep apnea syndrome in patients with long-term pacing: the European Multicenter Polysomnographic Study. *Circulation*, 2007, 115, s. 1703–1709.
- 51 Grimm, W. – Hoffmann, J. – Menz, V., et al.: Electrophysiologic evaluation of sinus node function and atrioventricular conduction in patients with prolonged ventricular asystole during obstructive sleep apnea. *Am J Cardiol*, 1996, 77, s. 1310–1314.
- 52 Koehler, U. – Fus, E. – Grimm, W., et al.: Heart block in patients with obstructive sleep apnoea: pathogenetic theories and effects of treatment. *Eur Respir J*, 1998, 11, s. 434–439.
- 53 Craig, S. – Pepperell, J. C. – Koulet, M., et al.: Continuous positive airway pressure treatment for obstructive sleep apnoea reduces resting heart rate but does not affect dysrhythmias: a randomised controlled trial. *J Sleep Res*, 2009, 18, s. 329–336.
- 54 Gami, A. S. – Pressman, G. – Caples, S. M., et al.: Association of atrial fibrillation and obstructive sleep apnea. *Circulation*, 2004, 110, s. 364–367.
- 55 Porthan, K. M. – Melin, J. H. – Kupila, J. T., et al.: Prevalence of sleep apnea syndrome in lone atrial fibrillation: a case-control study. *Chest*, 2004, 125, s. 879–885.
- 56 Moee, T. – Franklin, K. A. – Holmström, K., et al.: Sleep-disordered breathing and coronary artery disease: long-term prognosis. *Am J Respir Crit Care Med*, 2001, 164, s. 1910–1913.
- 57 Gami, A. S. – Hodge, D. O. – Herges, R. M., et al.: Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. *J Am Coll Cardiol*, 2007, 49, s. 565–571.
- 58 Javaheri, S.: Sleep disorders in systolic heart failure: a prospective study of 100 male patients. The final report. *Int J Cardiol*, 2006, 106, s. 21–28.
- 59 Javaheri, S. – Parker, T. J. – Liming, J. D., et al.: Sleep apnea in 81 ambulatory male patients with stable heart failure. Types and their prevalences, consequences, and presentations. *Circulation*, 1998, 97, s. 2154–2159.
- 60 Kanagala, R. – Murali, N. S. – Friedman, P. A., et al.: Obstructive sleep apnea and the recurrence of atrial fibrillation. *Circulation*, 2003, 107, s. 2589–2594.
- 61 Wang, T. J. – Parise, H. – Levy, D., et al.: Obesity and the risk of new-onset atrial fibrillation. *JAMA*, 2004, 292, s. 2471–2477.
- 62 Oliveira, W. – Campos, O. – Bezerra Lira-Filho, E., et al.: Left atrial volume and function in patients with obstructive sleep apnea assessed by real-time three-dimensional echocardiography. *J Am Soc Echocardiogr*, 2008, 21, s. 1355–1361.
- 63 Orban, M. – Bruce, C. J. – Pressman, G. S., et al.: Dynamic changes

- of left ventricular performance and left atrial volume induced by the Mueller maneuver in healthy young adults and implications for obstructive sleep apnea, atrial fibrillation, and heart failure. *Am J Cardiol*, 2008, 102, s. 1557–1561.
- 64 Koshino, Y. – Villarraga, H. R. – Orban, M., et al.: Changes in left and right ventricular mechanics during the Mueller maneuver in healthy adults: a possible mechanism for abnormal cardiac function in patients with obstructive sleep apnea. *Circ Cardiovasc Imaging*, 2010, 3, s. 282–289.
- 65 Shepard, J. W. Jr., – Garrison, M. W. – Grither, D. A., et al.: Relationship of ventricular ectopy to oxyhemoglobin desaturation in patients with obstructive sleep apnea. *Chest*, 1985, 88, s. 335–340.
- 66 Koshino, Y. – Satoh, M. – Katayose, Y., et al.: Association of sleep-disordered breathing and ventricular arrhythmias in patients without heart failure. *Am J Cardiol*, 2008, 101, s. 882–886.
- 67 Shepard, J. W. Jr. – Garrison, M. W. – Grither, D. A., et al.: Relationship of ventricular ectopy to oxyhemoglobin desaturation in patients with obstructive sleep apnea. *Chest*, 1985, 88, s. 335–340.
- 68 Monahan, K. – Storfer-Isser, A. – Mehra, R., et al.: Triggering of nocturnal arrhythmias by sleep-disordered breathing events. *J Am Coll Cardiol*, 2009, 54, s. 1797–1804.
- 69 Harbison, J. – O'Reilly, P. – McNicholas, W. T.: Cardiac rhythm disturbances in the obstructive sleep apnea syndrome: effects of nasal continuous positive airway pressure therapy. *Chest*, 2000, 118, s. 591–595.
- 70 Ryan, C. M. – Juvet, S. – Leung, R., et al.: Timing of nocturnal ventricular ectopy in heart failure patients with sleep apnea. *Chest*, 2008, 133, s. 934–940.
- 71 Bitter, T. – Westerheide, N. – Prinz, Ch., et al.: Cheyne–Stokes respiration and obstructive sleep apnoea are independent risk factors for malignant ventricular arrhythmias requiring appropriate cardioverter-defibrillator therapies in patients with congestive heart failure. *Eur Heart J*, 2011, 32, s. 61–74.
- 72 Young, T. – Finn, L. – Austin, D., et al.: Menopausal status and sleep-disordered breathing in the Wisconsin Sleep Cohort Study. *Am J Respir Crit Care Med*, 2003, 167, s. 1181–1185.
- 73 Levy, L. M. – Pepin, J. L. – Tamisier, R., et al.: Prevalence and impact of central sleep apnea in heart failure. *Sleep Med Clin*, 2007, 2, s. 615–621.
- 74 Bitter, T. – Faber, L. – Hering, D., et al.: Sleep-disordered breathing in heart failure with normal left ventricular ejection fraction. *Eur J Heart Fail*, 2009, 11, s. 602–608.
- 75 Herrscher, T. E. – Akre, H. – Øverland, B., et al.: High prevalence of sleep apnea in heart failure outpatients: even in patients with preserved systolic function. *J Card Fail*, 2011, 17, s. 420–425.
- 76 Arzt, M. – Young, T. – Finn, L., et al.: Sleepiness and sleep in patients with both systolic heart failure and obstructive sleep apnea. *Arch Intern Med*, 2006, 166, s. 1716–1722.
- 77 MacDonald, M. – Fang, J. – Pittman, S. D., et al.: The current prevalence of sleep-disordered breathing in congestive heart failure patients treated with beta-blockers. *J Clin Sleep Med*, 2008, 4, s. 38–42.
- 78 Javaheri, S. – Shukla, R. – Zeigler, H., et al.: Central sleep apnea, right ventricular dysfunction, and low diastolic blood pressure are predictors of mortality in systolic heart failure. *J Am Coll Cardiol*, 2007, 49, s. 2028–2034.
- 79 Yumino, D. – Wang, H. – Floras, J. S., et al.: Relationship between sleep apnoea and mortality in patients with ischaemic heart failure. *Heart*, 2009, 95, s. 819–824.
- 80 Lanfranchi, P. A. – Bagnoli, A. – Bosimini, E., et al.: Prognostic value of nocturnal Cheyne–Stokes respiration in chronic heart failure. *Circulation*, 1999, 99, s. 1435–1440.
- 81 Gabor, J. Y., et al.: Improvement in Cheyne–Stokes respiration following cardiac resynchronization therapy. *Eur Resp J*, 2005, s. 95–100.
- 82 Oldenburg, O. – Faber, L. – Vogt, J., et al.: Influence of cardiac resynchronization therapy on different types of sleep-disordered breathing. *Eur J Heart Fail*, 2007, 9, s. 820–826.
- 83 Kara, T. – Novak, M. – Nykodym, J., et al.: Short-term effects of cardiac resynchronization therapy on sleep-disordered breathing in patients with systolic heart failure. *Chest*, 2008, 134, s. 87–93.
- 84 Mansfield, D. R. – Solin, P. – Roebuck, T., et al.: The effect of successful heart transplant treatment of heart failure on central sleep apnea. *Chest*, 2003, 124, s. 1675–1681.
- 85 Javaheri, S. – Abraham, W. T. – Brown, C., et al.: Prevalence of obstructive sleep apnoea and periodic limb movement in 45 subjects with heart transplantation. *Eur Heart J*, 2004, 25, s. 260–266.
- 86 Sasayama, S. – Izumi, T. – Matsuzaki, M., et al.: Improvement of quality of life with nocturnal oxygen therapy in heart failure patients with central sleep apnea. *Circ J*, 2009, 73, s. 1255–1262.
- 87 Toyama, T. – Seki, R. – Kasama, S., et al.: Effectiveness of nocturnal home oxygen therapy to improve exercise capacity, cardiac function and cardiac sympathetic nerve activity in patients with chronic heart failure and central sleep apnea. *Int J Cardiol*, 2009, 73, s. 299–304.
- 88 Szollosi, I. – Jones, M. – Morrell, M. J., et al.: Effect of CO₂ inhalation on central sleep apnea and arousals from sleep. *Respiration*, 2004, 71, s. 493–498.
- 89 Lanfranchi, P. A. – Somers, V. K.: Sleep-disordered breathing in heart failure: characteristics and implications. *Respir Physiol Neurobiol*, 2003, 136, s. 153–165.
- 90 Kaneko, Y. – Floras, J. S. – Usui, K., et al.: Cardiovascular effects of continuous positive airway pressure in patients with heart failure and obstructive sleep apnea. *N Engl J Med*, 2003, 348, s. 1233–1241.
- 91 Bradley, T. D. – Logan, A. G. – Kimoff, R. J., et al.: Continuous positive airway pressure for central sleep apnea and heart failure. *N Engl J Med*, 2005, 353, s. 2025–2033.
- 92 Arzt, M. – Floras, J. S. – Logan, A. G., et al.: Suppression of central sleep apnea by continuous positive airway pressure and transplant-free survival in heart failure: a post hoc analysis of the Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure Trial. *Circulation*, 2007, 115, s. 3173–3180.
- 93 Teschler, H. – Dohring, J. – Wang, Y. M., et al.: Adaptive pressure support servo-ventilation: a novel treatment for Cheyne–Stokes respiration in heart failure. *Am J Respir Crit Care Med*, 2001, 164, s. 614–619.
- 94 Philippe, C. – Stoica-Herman, M. – Drouot, X., et al.: Compliance with and effectiveness of adaptive servoventilation versus continuous positive airway pressure in the treatment of Cheyne–Stokes respiration in heart failure over a six month period. *Heart*, 2006, 92, s. 337–342.
- 95 Kasai, T. – Usui, Y. – Yoshioka, T., et al.: Effect of flow-triggered adaptive servo-ventilation compared with continuous positive airway pressure in patients with chronic heart failure with coexisting obstructive sleep apnea and Cheyne–Stokes respiration. *Circ Heart Fail*, 2010, 3, s. 140–148.
- 96 Kasai, T. – Narui, K. – Dohi, T., et al.: Prognosis of patients with heart failure and obstructive sleep apnea treated with continuous positive airway pressure. *Chest*, 2008, 133, s. 690–696.
- 97 Randerath, W. J. – Nothofer, G. – Priegnitz, C., et al.: Long-term auto-servoventilation or constant positive pressure in heart failure and coexisting sleep with obstructive sleep apnea. *Chest*, 2012, 142, s. 440–447.
- 98 Miyata, M. – Yoshihisa, A. – Suzuki, S., et al.: Adaptive servo ventilation improves Cheyne–Stokes respiration, cardiac function, and prognosis in chronic heart failure patients with cardiac resynchronization therapy. *J Cardiol*, 2012, 60, s. 222–227.
- 99 Campbell, A. J. – Ferrier, K. – Neill, A. M.: Effect of oxygen versus adaptive pressure support servo-ventilation in patients with central sleep apnoea–Cheyne Stokes respiration and congestive heart failure. *Intern Med J*, 2012, 42, s. 1130–1136.
- 100 Pepperell, J. C. – Maskell, N. A. – Jones, D. R., et al.: A randomized controlled trial of adaptive ventilation for Cheyne–Stokes breathing in heart failure. *Am J Respir Crit Care Med*, 2003, 168, s. 1109–1114.
- 101 Kourouklis, S. P. – Vagiaklis, E. – Paraskevaidis, I. A., et al.: Effective sleep apnoea treatment improves cardiac function in patients with chronic heart failure. *Int J Cardiol*, 2013, 168, s. 157–162.
- 102 Arzt, M. – Schroll, S. – Series, F., et al.: Auto-servoventilation in heart failure with sleep apnoea: a randomised controlled trial. *Eur Respir J*, 2013, 42, s. 1244–1254.
- 103 Birner, C. – Series, F. – Lewis, K., et al.: Effects of auto-servo ventilation on patients with sleep-disordered breathing, stable systolic heart failure and concomitant diastolic dysfunction: subanalysis of a randomized controlled trial. *Respiration*, 2014, 87, s. 54–62.
- 104 Nakamura, S. – Asai, K. – Kubota, Y., et al.: Impact of sleep-disordered breathing and efficacy of positive airway pressure on mortality in patients with chronic heart failure and sleep-disordered breathing: a meta-analysis. *Clin Res Cardiol*, 2015, 104, s. 208–216.
- 105 Cowie, M. R. – Woehrle, H. – Wegscheider, K., et al.: Rationale and design of the SERVE-HF study: treatment of sleep-disordered breathing with predominant central sleep apnoea with adaptive servo-ventilation in patients with chronic heart failure. *Eur J Heart Fail*, 2013, 15, s. 937–943.
- 106 Cowie, M. R. – Woehrle, H. – Wegscheider, K., et al.: Adaptive servo-ventilation for central sleep apnea in systolic heart failure. *N Engl J Med*, 2015, 373, s. 1095–1105.

Subklinická hypotyreóza

prof. MUDr. Michal Kršek, CSc., MBA II. interní klinika 3. LF UK a FNKV, Praha

- 1 Canaris, G. J. – Manowitz, N. R. – Mayor, G., et al.: Colorado thyroid disease prevalence study. *Arch Intern Med*, 2000, 160, s. 526–534.
- 2 Vanderpump, M. P. – Tunbridge, W. M. – French, J. M., et al.: The incidence of thyroid disorders in the community: a twenty-year follow-up of the Wickham Survey. *Clin Endocrinol*, 1995, 43, s. 55–68.
- 3 Kim, Y. A. – Park, Y. J.: Prevalence and risk factors of subclinical thyroid disease. *Endocrinol Metab*, 2014, 29, s. 20–29.
- 4 Joffe, R. T. – Pearce, E. N. – Hennessey, J. V., et al.: Subclinical hypothyroidism, mood, and cognition in older adults: a review. *Int J Geriatr Psychiatry*, 2013, 28, s. 111–118.
- 5 Parle, J. – Roberts, L. – Wilson, S., et al.: A randomized controlled trial of the effect of thyroxine replacement on cognitive function in community-living elderly subjects with subclinical hypothyroidism: the Birmingham Elderly Thyroid Study. *J Clin Endocrinol Metab*, 2010, 95, s. 3623–3632.
- 6 Monzani, A. – Prodam, F. – Rapa, A., et al.: Endocrine disorders in childhood and adolescence. Natural history of subclinical hypothyroidism in children and adolescents and potential affect of replacement therapy: a review. *Eur J Endocrinol*, 2012, 168, s. R1–R11.
- 7 De Moura Souza, A. – Sichiari, R.: Association between serum TSH concentrations within normal range and adiposity. *Eur J Endocrinol*, 2011, 165, s. 11–15.
- 8 Nyrnes, A. – Jorde, R. – Sundsfjord, J.: Serum TSH is positively associated with BMI. *Int J Obes*, 2006, 30, s. 100–105.
- 9 Wolters, B. – Lass, N. – Reinehr, T.: TSH and free triiodothyronine concentrations are associated with weight loss in a lifestyle intervention and weight regain afterwards in obese children. *Eur J Endocrinol*, 2013, 168, s. 323–329.
- 10 Roos, A. – Bakker, S. J. – Links, T. P., et al.: Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. *J Clin Endocrinol Metab*, 2007, 92, s. 491–496.
- 11 Maratou, E. – Hadjidakis, D. J. – Kollias, A., et al.: Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. *Eur J Endocrinol*, 2009, 160, s. 787–790.
- 12 Stanická, S. – Vondra, K. – Pelikánová, T., et al.: Insulin sensitivity and counter-regulatory hormones in hypothyroidism and during thyroid hormone replacement therapy. *Clin Chem Lab Med*, 2005, 43, s. 715–720.
- 13 Boelaert, K. V. – Newby, P. R. – Simmonds, M. J., et al.: Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. *Am J Med*, 2010, 123, s. 183 e1–e9.
- 14 Perros, P. – Mc Crimmon, R. J. – Shaw, G., et al.: Frequency of thyroid dysfunction in diabetic patients: value of annual screening. *Diabet Med*, 1995, 12, s. 622–627.
- 15 Duntas, L. H. – Brenta, G.: The effect of thyroid disorders on lipid levels and metabolism. *Med Clin North Am*, 2012, 96, s. 269–281.
- 16 Pearce, E. N.: Update in lipid alterations in subclinical hypothyroidism. *J Clin Endocrinol Metab*, 2012, 97, s. 326–333.
- 17 Meier, C. – Staub, J. J. – Roth, C. B., et al.: TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study). *J Clin Endocrinol Metab*, 2001, 86, s. 4860–4866.
- 18 Monzani, F. – Caraccio, N. – Kozakowa, M., et al.: Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo-controlled study. *J Clin Endocrinol Metab*, 2004, 89, s. 2099–2106.
- 19 Monzani, F. – Di Bello, V. – Caraccio, N., et al.: Effect of L-thyroxine on cardiac function and structure in subclinical hypothyroidism: a double-blind, placebo-controlled study. *J Clin Endocrinol Metab*, 2001, 86, s. 1110–1115.
- 20 Biondi, B.: Mechanisms in endocrinology: heart failure and thyroid dysfunction. *Eur J Endocrinol*, 2012, 167, s. 609–618.
- 21 Taddei, S. – Caraccio, N. – Virdis, A., et al.: Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effects of L-thyroxine therapy. *J Clin Endocrinol Metab*, 2003, 88, s. 3731–3737.
- 22 Rodondi, N. – Bauer, D. C. – Cappola, A. R., et al.: Subclinical thyroid dysfunction, cardiac function, and the risk of heart failure. The Cardiovascular Health Study. *J Am Coll Cardiol*, 2008, 52, s. 1152–1159.
- 23 Vanderpump, M. P. – Tunbridge, W. M. – French, W. M., et al.: The development of ischemic heart disease in relation to autoimmune thyroid disease in a 20-year follow-up study of an English community. *Thyroid*, 1996, 6, s. 155–160.
- 24 Pearce, S. H. S. – Brabant, G. – Duntas, L. H., et al.: 2013 ETA guideline: management of subclinical hypothyroidism. *Eur Thyroid J*, 2013, 2, s. 2015–2228.

Současné možnosti a novinky v léčbě IPF

MUDr. Martina Šterclová, Ph.D. Pneumologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

- 1 Kärkkäinen, M. – Nurmi, H. – Kettunen, H. P., et al.: Underlying and immediate causes of death in patients with idiopathic pulmonary fibrosis. *BMC Pulm Med*, 2018, 18, s. 69.
- 2 Kärkkäinen, M. – Kettunen, H. P. – Nurmi, H., et al.: Effect of smoking and comorbidities on survival in idiopathic pulmonary fibrosis. *Respir Res*, 2017, 18, s. 160.
- 3 Schwartz, D. A.: Idiopathic pulmonary fibrosis a complex genetic disorder. *Trans Am Clin Climatol Assoc*, 2016, 127, s. 34–45.
- 4 Allen, R. J. – Porte, J. – Braybrooke, R., et al.: Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study. *Lancet Respir Med*, 2017, 5, s. 869–880.
- 5 Yang, I. V. – Fingerlin, T. E. – Evans, C. M., et al.: MUC5B and idiopathic pulmonary fibrosis. *Ann Am Thorac Soc*, 2015, 12, suppl. 2, s. 193–199.
- 6 Oldham, J. M. – Noth, I. – Martinez, F. J.: Pharmacogenetics and interstitial lung disease. *Curr Opin Pulm Med*, 2016, 22, s. 456–465.
- 7 Newton, C. A. – Molyneaux, P. L. – Oldham, J. M.: Clinical genetics in interstitial lung disease. *Front Med (Lausanne)*, 2018, 5, s. 116.
- 8 Newton, C. A. – Batra, K. – Torrealba, J., et al.: Telomere-related lung fibrosis diagnostically heterogeneous but uniformly progressive. *Eur Respir J*, 2016, 48, s. 1710–1720.
- 9 Shulgina, L. – Cahn, A. P. – Chilvers, E. R., et al.: Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial. *Thorax*, 2013, 68, s. 155–162.
- 10 Fastrès, A. – Felice, F. – Roels, E., et al.: The lung microbiome in idiopathic pulmonary fibrosis: a promising approach for targeted therapies. *Int J Mol Sci*, 2017, 18, s. 2735, <https://doi.org/10.3390/ijms18122735>.
- 11 Hammond, M. – Clark, A. B. – Cahn, A. P., et al.: The efficacy and mechanism evaluation of treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial. *Trials*, 2018, 19, s. 89.
- 12 Hilberg, O. – Bendstrup, E. – Ibsen, R., et al.: Economic consequences of idiopathic pulmonary fibrosis in Denmark. *ERJ Open Res*, 2018, 4, 00045-2017, DOI: 10.1183/23120541.00045-2017.
- 13 Ferrara, G. – Luppi, F. – Birring, S. S., et al.: Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions. *Eur Respir Rev*, 2018, 27.
- 14 Wernig, G. – Chen, S. Y. – Cui, L., et al.: Unifying mechanism for different fibrotic diseases. *Proc Natl Acad Sci U S A*, 2017, 114, s. 4757–4762.
- 15 Van den Blink, B. – Dillingham, M. R. – Ginns, L. C., et al.: Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy. *Eur Respir J*, 2016, 47, s. 889–897.

Chronická obstrukční plicní nemoc – nové možnosti léčby

MUDr. Václava Bártů, Ph.D. Plicní oddělení, Medicon, s. r. o., Praha

- 1 *Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017*. Dostupné z: <http://goldcopd.org>.
- 2 Roche, N. – Small, M. – Broomfield, S., et al.: Real World COPD: Association of meningeal symptoms with clinical and patient reported outcomes. *COPD*, 2013, 10, s. 679–686.
- 3 Mapel, D. W. – Dalal, A. A. – Blanchette, Ch. M., et al.: Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims. *Int J COPD*, 2011, 6, s. 573–581.
- 4 Kew, K. M. – Mavergames, C. – Walters, J. A.: Long-acting beta2-agonists for chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*, 2013, 10, CD0101177.
- 5 Vogelmeier, C. – Hederer, B. – Glaab, T., et al.: Tiotropium versus salmeterol for the prevention of exacerbation of COPD. *N Engl J Med*, 2011, 364, s. 1093–1103.
- 6 Thomas, M. – Halpin, D. – Miravittles, M.: When is dual bronchodilation indicated in COPD? *Int J Chron Obstruct Pulmon Dis*, 2017, 12, s. 2291–2305.
- 7 Pavord, I. D. – Lettis, S. – Locantore, N., et al.: Blood eosinophils and inhaled corticosteroid/long-acting beta-2 agonist efficacy in COPD. *Thorax*, 2016, 71, s. 118–125.
- 8 Halpin, D. – Miravittles, M. – Metzendorf, N., et al.: Impact and preventivity of severe exacerbations of COPD: a review of the evidence. *Int J Chron Obstruct Pulmon Dis*, 2017, 12, s. 2891–2908.
- 9 Miravittles, M. – Anzueto, A.: A new two-step algorithm for the treatment of COPD. *Eur Respir J*, 2017, 49, 1602200.
- 10 Klooster, K. – Slebos, D. J. – Zoumot, Z., et al.: Endobronchial valves for emphysema: an individual patient-level reanalysis of randomised controlled trials. *BMJ Open Res*, 2017, 4, e000214.
- 11 Marchetti, N. – Criner, G. J.: Surgical approaches to treating emphysema: lung volume reduction surgery, bullectomy, and lung transplantation. *Semin Respir Crit Care Med*, 2015, 36, s. 592–608.
- 12 Molimard, M. – Raheison, Ch. – Lignot, S., et al.: Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. *Eur Respir J*, 2017, 49, 1601794.

Postavení inhalačních kortikosteroidů v terapii chronické obstrukční plicní nemoci

MUDr. Michal Švarc Plicní klinika FN Hradec Králové, Plicní ambulance Edumed, s. r. o., Broumov

- 1 The Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report 2018, dostupné z: <https://goldcopd.org>.
- 2 Dostupné z: <http://www.who.int/en/news-room/fact-sheets/detail/the-top-10-causes-of-death>, vyhledáno 29. 8. 2018.
- 3 Burge, P. S.: Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. *BMJ*, 2000, 320, doi: <https://doi.org/10.1136/bmj.320.7245.1297>.
- 4 Wise, R. – Connett, J. – Weinmann, G., et al.: Lung Health Study Research Group: Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. *N Engl J Med*, 2000, 343, s. 1902–1909.
- 5 Calverley, P. M. A. – Anderson, J. A. – Celli, B., et al.: for the TORCH investigators: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. *N Engl J Med*, 2007, 356, s. 775–789.
- 6 Wedzicha, et al.: Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. *N Engl J Med*, 2016, 374, s. 2222–2234, DOI: 10.1056/NEJMoa1516385.
- 7 GINA 2018 Report Global Strategy for Asthma Management and Prevention, dostupné z: <https://ginasthma.org>.
- 8 Lange, P. – Colak, Y. – Ingebrigtsen, T. S., et al.: Long-term prognosis of asthma, chronic obstructive pulmonary disease, and asthma-chronic obstructive pulmonary disease overlap in the Copenhagen City Heart study: a prospective population-based analysis. *Lancet Respir Med*, 2016, 4, s. 454–462.
- 9 Lange, P., et al.: Long-term prognosis of asthma, chronic obstructive pulmonary disease, and asthma-chronic obstructive pulmonary disease overlap in the Copenhagen City Heart study: a prospective population-based analysis. *Lancet Respir Med*, 2016, 4, s. 454–462.
- 10 Welte, T., et al.: Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*, 2009, 180, s. 741–750, doi: 10.1164/rccm.200904-0492OC.
- 11 Vestbo, J. – Papi, A. – Corradi, M., et al.: Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. *Lancet*, 2017, 389, s. 1919–1929.
- 12 Singh, D. – Papi, A. – Corradi, M., et al.: Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. *Lancet*, 2016, 388, s. 963–973.
- 13 Papi, A. – Vestbo, J. – Fabbri, L., et al.: Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. *Lancet*, 2018, 391, s. 1076–1084.
- 14 Vestbo, J. – Anderson, J. A. – Brook, R. D., et al.: Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. *Lancet*, 2016, 387, s. 1817–1826.
- 15 Wang, Y.-F. – Liou, J. T. – Lin, C. W., et al.: Association of cardiovascular risk with inhaled long-acting bronchodilators in patients with chronic obstructive pulmonary disease: a nested case-control study. *JAMA Intern Med*, 2018, 178, s. 229–238.
- 16 Pavord, I. D. – Lettis, S. – Locantore, N., et al.: Blood eosinophils and inhaled corticosteroid/long-acting beta-2 agonist efficacy in COPD. *Thorax* 2016; 71:118–125.
- 17 Bafadhel, M. – Peterson, S. – De Blas, M. A., et al.: Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. *Lancet Respir Med* 2018; 6: 117–126.
- 18 Švarc, Koblížek, V. – Blažek, M.: Eozinofilie a možnosti predikce odpovědi na inhalační kortikosteroidy (IKS) u chronické obstrukční plicní nemoci (CHOPN). *Studia pneumologica et phthiseologica*. 2017, roč. 77, č. 1, s. 32–36. ISSN: 1213-810X.
- 19 Loke, Y. K. – Cavallazzi, R. – Singh, S.: Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. *Thorax*. 2011 Aug;66(8):699–708.
- 20 Wang, Ch.-Y. – Lai, Ch.-Ch. – Yang, W.-Ch., et al.: The association between inhaled corticosteroid and pneumonia in COPD patients: the improvement of patients' life quality with COPD in Taiwan (IMPACT) study. *Int J Chron Obstruct Pulmon Dis*. 2016; 11: 2775–2783.
- 21 Suissa, S. – Patenaude, V. – Lapi, F., et al.: Inhaled corticosteroids in COPD and the risk of serious pneumonia. *Thorax*. 2013 Nov;68(11):1029–1036.
- 22 Perrone, V. – Sangiorgi, D. – Buda, S., et al.: Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting. *Int J Chron Obstruct Pulmon Dis*. 2016 Nov 4;11:2749–2755.

Selektivní screening Fabryho, Pompeho a Gaucherovy choroby ze suchých krevních kapek u dospělých a dospívajících

MUDr. Martin Hřebíček, Ph.D. | Ing. Helena Poupětová | Ing. Jitka Honzíková | RNDr. Jana Ledvinová, CSc.

Laboratoř pro studium vzácných nemocí a Diagnostické laboratoře DMP – Enzymologická laboratoř, Klinika dětského a dorostového lékařství UK v Praze, 1. LF a VFN, Praha

- 1 Chamoles, N. A. – Blanco, M. – Gaggioli, D.: Fabry disease: enzymatic diagnosis in dried blood spots on filter paper. *Clinica Chimica Acta*, 2001, 308, s. 195–196, doi: 10.1016/S0009-8981(01)00478-8.
- 2 Jesus, V. R. D. – Zhang, X. K. – Keutzer, J., et al.: Development and evaluation of quality control dried blood spot materials in newborn screening for lysosomal storage disorders. *Clinical Chemistry*, 2009, 55, s. 158–164, doi: 10.1373/clinchem.2008.111864.
- 3 Reuser, A. J. – Verheijen, F. W. – Bali, D., et al.: The use of dried blood spot samples in the diagnosis of lysosomal storage

- disorders – Current status and perspectives. *Molecular Genetics and Metabolism*, 2011, 104, s. 144–148, doi: 10.1016/j.ymgme.2011.07.014.
- 4 Van der Tol, L. – Smid, B. E. – Poorthuis, B. J. H. M., et al.: A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance. *J Med Genetics*, 2014, 51, s. 1–9, doi: 10.1136/jmedgenet-2013-101857.
 - 5 Bodamer, O. A. – Hung, Ch. Y.: The diagnostic path to Pompe disease. *US Neurology*, 2014, 10, s. 44–47, doi: http://doi.org/10.17925/USN.2014.10.01.44.
 - 6 Linthorst, G. E. – Hollak, C. E. M. – Korevaar, J. C., et al.: Alpha-galactosidase A deficiency in Dutch patients on dialysis: a critical appraisal of screening for Fabry disease. *Nephrol Dial Transplant*, 2003, 18, s. 1581–1584.
 - 7 Rolf, A. – Böttcher, T. – Zschiesche, M., et al.: Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. *Lancet*, 2015, 366, s. 1794–1796, doi: 10.1016/S0140-6736(05)67635-0.
 - 8 Bodamer, O. A. – Hung, C. Y. – John, T.: The diagnostic path to Pompe disease. *US Neurology*, 2014, 10, s. 44, doi: 10.17925/USN.2014.10.01.44.
 - 9 Germain, D. P.: Fabry disease. *Orphanet Journal of Rare Diseases*, 2010, 5, s. 30, doi: 10.1186/1750-1172-5-30.
 - 10 Wilcox, W. R. – Oliveira, J. P. – Hopkin, R. J., et al.: Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry. *Molecular Genetics and Metabolism*, 2008, 93, s. 112–128, doi: 10.1016/j.ymgme.2007.09.013.
 - 11 Dobrovolny, R. – Dvorakova, L. – Ledvinova, J., et al.: Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the α -galactosidase A gene in the Czech and Slovak population. *J Mol Med*, 2005, 83, s. 647–654, doi: 10.1007/s00109-005-0656-2.
 - 12 Ogawa, K. – Sugamata, K. – Funamoto, N., et al.: Restricted accumulation of globotriaosylceramide in the hearts of atypical cases of Fabry's disease. *Human Pathology*, 1990, 21, s. 1067–1073, doi: 10.1016/0046-8177(90)90258-7.
 - 13 Elleder, M. – Bradová, V. – Smid, F., et al.: Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. *Virchows Arch A Pathol Anat Histopathol*, 1990, 417, s. 449–455.
 - 14 Desnick, R. J. – Banikazemi, M. – Wasserstein, M.: Enzyme replacement therapy for Fabry disease, an inherited nephropathy. *Clin Nephrol*, 2002, 57, s. 1–8.
 - 15 Nakao, S. – Kodama, C. – Takenaka, T., et al.: Fabry disease: Detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype 1. *Kidney International*, 2002, 64, s. 801–807, doi: 10.1046/j.1523-1755.2003.00160.x.
 - 16 Giacomini, P. S. – Shannon, P. T. – Clarke, J. T. R., et al.: Fabry's disease presenting as stroke in a young female. *Can J Neurol Sci*, 2004, 31, s. 112–114.
 - 17 Schiffmann, R. – Hughes, D. A. – Linthorst, G. E., et al.: Screening, diagnosis, and management of patients with Fabry disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. *Kidney International*, 2017, 91, s. 284–293, doi: 10.1016/j.kint.2016.10.004.
 - 18 Spada, M. – Pagliardini, S. – Yasuda, M., et al.: High incidence of later-onset Fabry disease revealed by newborn screening. *Am J Human Genetics*, 2006, 79, s. 31–40, doi: 10.1086/504601.
 - 19 Chien, Y.-H. – Lee, N.-C. – Chiang, S.-C., et al.: Fabry disease: incidence of the common later-onset α -galactosidase A IVS4+919G→A mutation in Taiwanese newborns—superiority of DNA-based to enzyme-based newborn screening for common mutations. *Mol Med*, 2012, 18, s. 780–784, doi: 10.2119/molmed.2012.00002.
 - 20 Doheny, D. – Srinivasan, R. – Pagant, S., et al.: Fabry Disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995–2017. *J Med Genetics*, 2018, 55, s. 261–268, doi: 10.1136/jmedgenet-2017-10508.
 - 21 Kishnani, P. S. – Steiner, R. D. – Bali, D., et al.: Pompe disease diagnosis and management guideline. *Genet Med*, 2006, 8, s. 267–288, doi: 10.1097/01.gim.0000218152.87434.f3.
 - 22 Hobson-Webb, L. D. – Kishnani, P. S.: How common is misdiagnosis in late-onset pompe disease? *Muscle Nerve*, 2012, 45, s. 301–302, doi: 10.1002/mus.22296.
 - 23 O'Callaghan, C. – Henderson, R. – Masel, P., et al.: Adult-onset Pompe's disease presenting with insidious hypercapnic respiratory failure. *Respir Case Rep*, 2016, 4, e00178, doi: 10.1002/rrcr.2178.
 - 24 Chan, J. – Desai, A. K. – Kazi, Z. B., et al.: The emerging phenotype of late-onset Pompe disease: A systematic literature review. *Molecular Genetics and Metabolism*, 2017, 120, s. 163–172, doi: 10.1016/j.ymgme.2016.12.004.
 - 25 Hobson-Webb, L. D. – Austin, S. L. – Jain, S., et al.: Small-fiber neuropathy in Pompe disease: first reported cases and prospective screening of a clinic cohort. *Am J Case Rep*, 2015, 16, s. 196–201, doi: 10.12659/AJCR.893309.
 - 26 Ausems, M. G. – Lochman, P. – van Diggelen, O. P., et al.: A diagnostic protocol for adult-onset glycogen storage disease type II. *Neurology*, 1999, 55, s. 851–853.
 - 27 Rosenbloom, B. E. – Weinreb, N. J.: Bone disease in patients with Gaucher disease. Gaucher Disease: A Comprehensive Review. *CRO*, 2014, 18, doi: 10.1615/CritRevOncog.2013006060.
 - 28 Schiffmann, R.: Chapter 26 – Gaucher Disease: Neuropathic Forms. In: Rosenberg, R. N. – Pascual, J. M. (eds): *Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease*. Academic Press, Boston, 2015, s. 301–311.
 - 29 O'Regan, G. – deSouza, R.-M. – Balestrino, R., et al.: Glucocerebrosidase mutations in Parkinson disease. *J Parkinson's Disease*, 2017, 7, s. 411–422, doi: 10.3233/JPD-171092.
 - 30 Hollak, C. E. – Weely, S. – van Oers, M. H., et al.: Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. *J Clin Invest*, 1994, 93, s. 1288–1292, doi: 10.1172/JCI117084.
 - 31 Oemardien, L. F. – Boer, A. M. – Ruijter, G. J. G., et al.: Hemoglobin precipitation greatly improves 4-methylumbelliferone-based diagnostic assays for lysosomal storage diseases in dried blood spots. *Molecular Genetics and Metabolism*, 2011, 102, s. 44–48, doi: 10.1016/j.ymgme.2010.09.008.
 - 32 Li, Y. – Scott, C. R. – Chamoles, N. A., et al.: Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening. *Clinical Chemistry*, 2004, 50, s. 1785–1796, doi: 10.1373/clinchem.2004.035907.
 - 33 Finsterer, J. – Stöllberger, C. – Voigtländer, T.: Comparison of two tests for serum α -galactosidase in nonneuromuscular left ventricular hypertrophy / noncompaction. *Jpn Heart J*, 2004, 45, s. 179–181, doi: 10.1536/jhj.45.179.
 - 34 Okumiya, T. – Keulemans, J. L. M. – Kroos, M. A., et al.: A new diagnostic assay for glycogen storage disease type II in mixed leukocytes. *Molecular Genetics and Metabolism*, 2006, 88, s. 22–28, doi: 10.1016/j.ymgme.2005.10.016.
 - 35 Labrousse, P. – Chien, Y.-H. – Pomponio, R. J., et al.: Genetic heterozygosity and pseudodeficiency in the Pompe disease newborn screening pilot program. *Molecular Genetics and Metabolism*, 2010, 99, s. 379–383, doi: 10.1016/j.ymgme.2009.12.014.
 - 36 Van Diggelen, O. P. – Oemardien, L. F., et al.: Enzyme analysis for Pompe disease in leukocytes; superior results with natural substrate compared with artificial substrates. *J Inher Metab Dis*, 2009, 32, s. 416–423, doi: 10.1007/s10545-009-1082-3.
 - 37 Yasuda, M. – Shabbeer, J. – Benson, S. D., et al.: Fabry disease: Characterization of α -galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele. *Hum Mutat*, 2003, 22, s. 486–492, doi: 10.1002/humu.10275.
 - 38 Froissart, R. – Guffon, N. – Vanier, M. T., et al.: Fabry disease: D313Y is an α -galactosidase A sequence variant that causes pseudodeficient activity in plasma. *Molecular Genetics and Metabolism*, 2003, 80, s. 307–314, doi: 10.1016/S1096-7192(03)00136-7.
 - 39 Poupětová, H. – Ledvinová, J. – Berná, L., et al.: The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations. *J Inher Metab Dis*, 2003, 33, s. 387–396, doi: 10.1007/s10545-010-9093-7.
 - 40 Merta, M. – Reiterova, J. – Ledvinova, J., et al.: A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population. *Nephrol Dial Transplant*, 2007, 22, s. 179–186, doi: 10.1093/ndt/gfl528.
 - 41 Paleček, T. – Honziková, J. – Poupětová, H., et al.: Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS). *J Inher Metab Dis*, 2014, 37, s. 455–460, doi: 10.1007/s10545-013-9659-2.
 - 42 Ošlejšková, D. H. – Rusnáková, Š. – Vohánka, S., et al.: Pompeho choroba v České republice – projekt screeningového vyšetření krve u rizikových pacientů pomocí „suché krevní kapky“. *Neurologie pro praxi*, 2009, 10, s. 102–106.